Shark Tank had the power of celebrity to convince viewers that they should care about venture capitalists and startup pitches. It will take a smart social media campaign or a crowdfunded super star (know any?) to get people to watch RealityCrowdTV. The idea of getting friends, relatives and strangers to give you money to launch […]
This is the transcript of my recent podcast with EarlySense’s president, Tim O’Malley. David E. Williams: This is David Williams, president of Health Business Group. I’m speaking with Tim O’Malley, president of EarlySense. Tim, thanks for joining me today. Tim O’Malley: Thanks, David, for having me on. Williams: Tim, can you explain, what is EarlySense? […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The money is still out there, but don’t take it until you absolutely have to. That was the advice to healthcare startups from Fahd M.T. Riaz, a partner in Morgan Lewis’s Business and Finance Practice. He talked about trends in funding for healthcare startups on a panel at CONVERGE with Kelly Campbell Slone of the […]
A Boston-area startup emerged from the depths of stealth mode today touting a $7 million financing round that will help it move toward clinical trials of a drug that would treat attention-deficit/hyperactivity disorder (ADHD) without addictive side effects. EB-1020, Neurovance Inc.’s lead drug candidate for ADHD, acts on three neurotransmitters: norepinephrine, dopamine and serotonin. Other […]
North Carolina life science companies hauled in more than $1.1 billion worth of investments and grant money in the last year, according to a report from the North Carolina Biosciences Organization. NCBIO, a Durham, North Carolina-based trade group, presented the figures to state legislators at a briefing for North Carolina lawmakers. The group conducts the […]
Updated 6:47 p.m. Small molecule discovery and development company Akebia Therapeutics Inc. reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting the round to $17 million. Startup Akebia is racing to the […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Radiopharmaceuticals company Cellectar Inc. has enrolled the last of eight patients in a Phase 1 trial of its cancer-treating drug candidate. The trial is designed to measure drug safety and dosimetry of Cellectar’s lead compound, called CLR1404. Dosimetry refers to the measurement of doses, which also allows investigators to understand how a drug will affect […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cellectar Inc. has raised $2.7 million for its radiopharmaceutical technology that treats and detects a variety of cancers, according to a regulatory filing. The company's lead compound is currently in Phase 1 clinical trials for cancer treatment.
The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems -- a side effect of some cancer treatments.
John Coffey, NanoBio's vice president for business development, said "we have three of the most significant global pharmaceutical companies in negotiations and they are seriously interested." A deal could come in the next few months.